DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

November 1, 2006

FILE COPY

Kip Vought
Regulus Pharmaceutical Consulting, Inc.
4840 Pearl East Circle
Suite 201E
Boulder, Colorado 80301

Dear Mr. Vought:

Your petition requesting the Food and Drug Administration to determine whether Mivacron - EQ 2 mg base/mL (NDA 20-098), held by Abbott Laboratories, Inc. has been voluntarily withdrawn from sale for safety or efficacy reasons, was received by this office on 10/31/2006. It was assigned docket number 2006P-0445/CP 1 and it was filed on 10/31/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P-0445

ACK 1